Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 179643, 10 pages
http://dx.doi.org/10.1155/2013/179643
Research Article

Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats

Department of Clinical Pharmacology, School of Medicine, Zhengzhou University, Daxue Road 40, Zhengzhou, Henan 450052, China

Received 13 December 2012; Revised 24 February 2013; Accepted 3 April 2013

Academic Editor: Kanokwan Jarukamjorn

Copyright © 2013 Xin Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Li, G. Lin, and Z. Zuo, “Pharmacological effects and pharmacokinetics properties of Radix Scutellariae and its bioactive flavones,” Biopharmaceutics & Drug Disposition, vol. 32, no. 8, pp. 427–445, 2011. View at Google Scholar
  2. S. P. Boyle, P. J. Doolan, C. E. Andrews, and R. G. Reid, “Evaluation of quality control strategies in Scutellaria herbal medicines,” Journal of Pharmaceutical and Biomedical Analysis, vol. 54, no. 5, pp. 951–957, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Gao, K. Huang, and H. Xu, “Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells,” Pharmacological Research, vol. 43, no. 2, pp. 173–178, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Ikemoto, K. Sugimura, N. Yoshida et al., “Antitumor effects of Scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines,” Urology, vol. 55, no. 6, pp. 951–955, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. D. L. Evers, C. F. Chao, X. Wang, Z. Zhang, S. M. Huong, and E. S. Huang, “Human cytomegalovirus-inhibitory flavonoids: studies on antiviral activity and mechanism of action,” Antiviral Research, vol. 68, no. 3, pp. 124–134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. Z. Lixuan, D. Jingcheng, Y. Wenqin, H. Jianhua, L. Baojun, and F. Xiaotao, “Baicalin attenuates inflammation by inhibiting NF-κB activation in cigarette smoke induced inflammatory models,” Pulmonary Pharmacology and Therapeutics, vol. 23, no. 5, pp. 411–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Xu, Y. Feng, H. Li, and Z. Gao, “Ferric citrate CYP2E1-independently promotes alcohol-induced apoptosis in HepG2 cells via oxidative/nitrative stress which is attenuated by pretreatment with baicalin,” Food and Chemical Toxicology, vol. 50, no. 9, pp. 3264–3272, 2012. View at Google Scholar
  8. P. Parajuli, N. Joshee, A. M. Rimando, S. Mittal, and A. K. Yadav, “In vitro antitumor mechanisms of various Scutellaria extracts and constituent flavonoids,” Planta Medica, vol. 75, no. 1, pp. 41–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Wu, A. Sun, and R. Liu, “Separation and purification of baicalin and wogonoside from the Chinese medicinal plant Scutellaria baicalensis Georgi by high-speed counter-current chromatography,” Journal of Chromatography A, vol. 1066, no. 1-2, pp. 243–247, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich, “Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians,” Journal of Pharmacology and Experimental Therapeutics, vol. 270, no. 1, pp. 414–423, 1994. View at Google Scholar · View at Scopus
  11. W. Tang and R. A. Stearns, “Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions,” Current Drug Metabolism, vol. 2, no. 2, pp. 185–198, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Vuppugalla, Y. Zhang, S. Chang, A. D. Rodrigues, and P. H. Marathe, “Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats,” Xenobiotica, vol. 42, no. 11, pp. 1058–1068, 2012. View at Publisher · View at Google Scholar
  13. P. Kremers, “Can drug-drug interactions be predicted from in vitro studies?” The Scientific World Journal, vol. 2, pp. 751–766, 2002. View at Google Scholar · View at Scopus
  14. D. H. Na, H. Y. Ji, E. J. Park, M. S. Kim, K. H. Liu, and H. S. Lee, “Evaluation of metabolism-mediated herb-drug interactions,” Archives of Pharmacal Research, vol. 34, no. 11, pp. 1829–1842, 2011. View at Google Scholar
  15. L. H. Pao, O. Y. Hu, H. Y. Fan, C. C. Lin, L. C. Liu, and P. W. Huang, “Herb-drug interaction of 50 Chinese herbal medicines on CYP3A4 activity in vitro and in vivo,” The American Journal of Chinese Medicine, vol. 40, no. 1, pp. 57–73, 2012. View at Google Scholar
  16. M. Y. Lai, S. L. Hsiu, Y. C. Hou, S. Y. Tsai, and P. D. L. Chao, “Significant decrease of cyclosporine bioavailability in rats caused by a decoction of the roots of Scutellaria baicalensis,” Planta Medica, vol. 70, no. 2, pp. 132–137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. F. Ueng, C. C. Shyu, Y. L. Lin, S. S. Park, J. F. Liao, and C. F. Chen, “Effects of baicalein and wogonin on drug-metabolizing enzymes in C57BL/6J mice,” Life Sciences, vol. 67, no. 18, pp. 2189–2200, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. A. Cho, J. S. Choi, and J. P. Burm, “Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein,” Pharmacological Reports, vol. 63, no. 4, pp. 1066–1073, 2011. View at Google Scholar
  19. T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer, “Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4,” Molecular Pharmacology, vol. 36, no. 1, pp. 89–96, 1989. View at Google Scholar · View at Scopus
  20. K. E. Thummel, D. D. Shen, T. D. Podoll et al., “Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation,” Journal of Pharmacology and Experimental Therapeutics, vol. 271, no. 1, pp. 557–566, 1994. View at Google Scholar · View at Scopus
  21. J. C. Gorski, S. D. Hall, D. R. Jones, M. Van Den Branden, and S. A. Wrighton, “Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily,” Biochemical Pharmacology, vol. 47, no. 9, pp. 1643–1653, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Kobayashi, K. Urashima, N. Shimada, and K. Chiba, “Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat,” Biochemical Pharmacology, vol. 63, no. 5, pp. 889–896, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Ghosal, H. Satoh, P. E. Thomas, E. Bush, and D. Moore, “Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450,” Drug Metabolism and Disposition, vol. 24, no. 9, pp. 940–947, 1996. View at Google Scholar · View at Scopus
  24. A. Ghosal, N. Sadrieh, L. Reik, W. Levin, and P. E. Thomas, “Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin,” Archives of Biochemistry and Biophysics, vol. 332, no. 1, pp. 153–162, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Zhang, R. E. Galinsky, R. E. Kimura, S. K. Quinney, D. R. Jones, and S. D. Hall, “Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats,” Drug Metabolism and Disposition, vol. 38, no. 1, pp. 61–72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. R. M. Franke, S. D. Baker, R. H. Mathijssen, E. G. Schuetz, and A. Sparreboom, “Influence of solute carriers on the pharmacokinetics of CYP3A4 probes,” Clinical Pharmacology and Therapeutics, vol. 84, no. 6, pp. 704–709, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. L. P. Volak, M. J. Hanley, G. Masse et al., “Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers,” British Journal of Clinical Pharmacology, vol. 75, no. 2, pp. 450–462, 2013. View at Google Scholar
  28. M. Hoch, P. Hoever, F. Alessi, R. Theodor, and J. Dingemanse, “Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects,” European Journal of Clinical Pharmacology, vol. 69, no. 3, pp. 523–532, 2013. View at Google Scholar
  29. C. L. Litterst, E. G. Mimnaugh, R. L. Reagan, and T. E. Gram, “Drug metabolism by microsomes from extrahepatic organs of rat and rabbit prepared by calcium aggregation,” Life Sciences, vol. 17, no. 5, pp. 813–818, 1975. View at Google Scholar · View at Scopus
  30. J. Jurica, M. Dostálek, J. Konecný, Z. Glatz, E. Hadasová, and J. Tomandl, “HPLC determination of midazolam and its three hydroxy metabolites in perfusion medium and plasma from rats,” Journal of Chromatography B, vol. 852, no. 1-2, pp. 571–577, 2007. View at Google Scholar
  31. Y. Tang, H. Zhu, Y. Zhang, and C. Huang, “Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography,” Biomedical Chromatography, vol. 20, no. 10, pp. 1116–1119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. D. A. Kennedy and D. Seely, “Clinically based evidence of drugherb interactions: a systematic review,” Expert Opinion on Drug Safety, vol. 9, no. 1, pp. 79–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. S. V. Mandlekar, A. V. Rose, G. Cornelius et al., “Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates,” Xenobiotica, vol. 37, no. 9, pp. 923–942, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. K. E. Kenworthy, J. C. Bloomer, S. E. Clarke, and J. B. Houston, “CYP3A4 drug interactions: correlation of 10 in vitro probe substrates,” British Journal of Clinical Pharmacology, vol. 48, no. 5, pp. 716–727, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Xing, X. Chen, and D. Zhong, “Absorption and enterohepatic circulation of baicalin in rats,” Life Sciences, vol. 78, no. 2, pp. 140–146, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Li, Q. Wang, X. Yao, and Y. Li, “Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- and pregnane X receptor-mediated pathways,” European Journal of Pharmacology, vol. 640, no. 1–3, pp. 46–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. N. Hou, X. Y. Zhu, and G. F. Cheng, “Effects of baicalin on liver microsomal cytochrome P450 system,” Yao Xue Xue Bao, vol. 35, no. 12, pp. 890–892, 2000. View at Google Scholar · View at Scopus
  38. T. Akao, K. Kawabata, E. Yanagisawa et al., “Baicalin, the predominant flavone glucuronide of Scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form,” Journal of Pharmacy and Pharmacology, vol. 52, no. 12, pp. 1563–1568, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. P. K. Honig, D. C. Wortham, K. Zamani, D. P. Conner, J. C. Mullin, and L. R. Cantilena, “Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences,” Journal of the American Medical Association, vol. 269, no. 12, pp. 1513–1518, 1993. View at Publisher · View at Google Scholar · View at Scopus
  40. H. H. Kupferschmidt, H. R. Ha, W. H. Ziegler, P. J. Meier, and S. Krähenbühl, “Interaction between grapefruit juice and midazolam in humans,” Clinical Pharmacology & Therapeutics, vol. 58, no. 1, pp. 20–28, 1995. View at Google Scholar
  41. J. H. Lin and A. Y. H. Lu, “Interindividual variability in inhibition and induction of cytochrome P450 enzymes,” Annual Review of Pharmacology and Toxicology, vol. 41, pp. 535–567, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Tang, J. H. Lin, and A. Y. H. Lu, “Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?” Drug Metabolism and Disposition, vol. 33, no. 5, pp. 603–613, 2005. View at Publisher · View at Google Scholar · View at Scopus